REG - Ondine Biomedical - Appointment of Interim Chief Financial Officer

Ondine BiomedicalAnnouncement

28/03/2024 13:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240328:nRSb7565Ia&default-theme=true

RNS Number : 7565I  Ondine Biomedical Inc.  28 March 2024

ONDINE BIOMEDICAL INC.

 

("Ondine Biomedical", "Ondine" or the "Company")

 

Appointment of Interim Chief Financial Officer

 

 

Ondine Biomedical Announces the Appointment of Kwong Choo as Interim Chief
Financial Officer

 

Ondine Biomedical Inc. (LON: OBI), the Canadian Life Sciences company
pioneering light-activated antimicrobial treatments, announces the appointment
of Kwong Choo as Interim Chief Financial Officer, following the resignation of
previous CFO J. P. Errico.

Mr. Choo, CPA, CIMA, brings more than 15 years of experience in international
public companies on NASDAQ, the Toronto Stock Exchange, and the TSX Venture
Exchange, as well as with a number of private biotechnology and pharmaceutical
companies. Mr. Choo has been working with Ondine since 2022.

Nikita Parkhaev CPA has been appointed as Vice President, Finance. Mr.
Parkhaev most recently held the position of Controller at Ondine. Elaine Lei
CPA has been appointed as corporate Controller; Ms. Lei previously held a
management position at KPMG LLP.

 

Additional appointments:

 

William (Bill) Kanz has been appointed as Senior Vice President, Engineering
and Operations. In this role, Mr. Kanz will lead the engineering, operations
and manufacturing teams, supporting Ondine's rapid commercial growth. Mr. Kanz
is a certified quality engineer and lean six-sigma black belt, and brings a
wealth of product management, manufacturing, and product development expertise
to the company.  Building on his operational management capabilities, he has
developed some of the world's leading atherectomy devices, ultrasound
catheters and blood pumps, and has 47 patents to his name.

Caetano Sabino, Ph.D. has been appointed as Ondine's Director of Research and
Development, building on his extensive pharmaceutical sciences background and
many years of development of light-activated therapeutics.  Dr. Sabino is an
expert in photodynamic disinfection, and has authored numerous important
publications, textbooks, and patents in the field.  He most recently held the
position of CEO, BioLambda, Científica e Comercial LTDA, Sao Paulo, Brazil
manufacturing industrial equipment for light-based disinfection in hospitals,
clinics, and the food industry.

 

Carolyn Cross, CEO, Ondine Biomedical commented.  "We will be providing an
update on our upcoming dual priorities of continued significant commercial
expansion and initiation of Phase 3 clinical trial in the USA with our
partner, HCA Healthcare."

*ENDS*

Enquiries:

 

 Ondine Biomedical Inc.
 Angelika Vance, Corporate Communications                      +001 (604) 838 2702

 Singer Capital Markets (Nominated Adviser and Joint Broker)
 Aubrey Powell, Sam Butcher                                    +44 (0)20 7496 3000

 RBC Capital Markets (Joint Broker)
 Rupert Walford, Kathryn Deegan                                +44 (0)20 7653 4000

 Vane Percy & Roberts (Media Contact)
 Simon Vane Percy, Amanda Bernard                              +44 (0)77 1000 5910

 

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian life science company innovating in the
field of photodisinfection therapies. Ondine has a pipeline of investigational
products, based on its proprietary photodisinfection platform, in various
stages of development. Ondine's nasal photodisinfection technology is approved
in several jurisdictions under the brand name Steriwave®. It has been awarded
the CE mark and, in the US, has been granted Qualified Infectious Disease
Product designation and Fast Track status by the FDA. Products beyond nasal
photodisinfection include therapies for a variety of medical indications such
as chronic sinusitis, ventilator-associated pneumonia, burns, and other
indications.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOASEUFEAELSELD